Genoskin strengthens governance with appointment of industry leader Fabrice Bouteille, a strategic milestone reinforcing independence, global growth, and leadership in human-relevant research.
At the 2026 annual meeting of the Society Of Toxicology (SOT), we will present new data demonstrating the value of our HypoSkin® ex vivo human skin platform as a translational human-based New Approach Methodology (NAM) for early safety assessment. The poster, developed in collaboration with argenx, will highlight how our platform can support early local tolerance screening and help reduce reliance on animal testing in formulation safety evaluation.
Explore how NativeSkin® supports ethical, human-relevant, and translational research in UV testing, phototoxicity assessment, and photobiology.